Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters’ Levels, but Has No Effect on Body Composition Parameters
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Dosing Regimen of Anti-IL-17 Therapies
2.3. Evaluation of Data
3. Results
3.1. Patients’ Characteristics
3.2. Clinical and Laboratory Findings
3.3. Body-Composition Analyses
3.4. Comparing Body Composition and Laboratory Parameters between Subgroups of Patients Treated with Secukinumab or Ixekizumab
3.5. Comparing Body-Composition Parameters between Subgroups of Patients Previously Treated with Anti-TNF or Ustekinumab Therapy
3.6. Correlation Analysis of Clinical, Body-Composition, and Laboratory Parameters
4. Discussion
5. Conclusions
6. Study Limitations
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
Th | T helper |
TNF | tumour necrosis factor |
IFN-γ | interferon gamma |
IL | interleukin |
BMI | body mass index |
HDL-cholesterol | high-density lipoprotein-cholesterol |
BFM | body fat mass |
FFM | fat-free mass |
SMM | skeletal muscle mass |
TBW | total body water |
ICW | intracellular water |
ECW | extracellular water |
BCM | body cell mass |
FFMI | fat-free mass index |
BFMI | body fat mass index |
SMMI | skeletal muscle mass index |
BIA | bioelectrical impedance analyzer |
PA | phase angle |
LDL-cholesterol | low-density lipoprotein-cholesterol |
ALT | alanine aminotransferase |
AST | aspartate aminotransferase |
GGT | gamma glutamyl transferase |
CRP | c-reactive protein |
ESR | erythrocyte sedimentation rate |
PASI | psoriasis area severity index |
DLQI | dermatology life-quality index |
HbA1c% | haemoglobin A1c% |
BFP | body fat percent |
IQR | interquartile ranges |
MTX | methotrexate |
FTO gene rs9939609 | alpha-ketoglutarate-dependent dioxygenase gene rs9939609 variant |
NAFLD | non-alcholic fatty liver disease |
IL-17R | interleukin-17 receptor |
LPS | lipopolysaccharide |
CCL | CC chemokine ligand |
mAb | monoclonal antibody |
VOYAGE 1 study | A study of guselkumab in the treatment of participants with moderate to severe plaque-type psoriasis |
VOYAGE 2 study | A study of guselkumab in the treatment of participants with moderate to severe plaque-type psoriasis with randomized withdrawal and retreatment |
UltIMMA-1 study | BI 655066 (risankizumab) compared to placebo and active comparator (ustekinumab) in patients with moderate to severe chronic plaque psoriasis |
UltIMMA-2 study | BI 655066 versus placebo and active comparator (ustekinumab) in patients with moderate to severe chronic plaque psoriasis |
FIXTURE | Safety and efficacy of secukinumab compared to etanercept in subjects With moderate to severe, chronic, plaque-type psoriasis |
ERASURE | Efficacy and safety of subcutaneous secukinumab for moderate to severe chronic plaque-type psoriasis for up to 1 year |
SCULPTURE | Efficacy and safety of subcutaneous secukinumab (AIN457) for moderate to severe chronic plaque-type psoriasis assessing different doses and dose regimens |
hs-CRP | high-sensitivity c-reactive protein |
UNCOVER-1,2 | A phase 3 study in participants with moderate to severe psoriasis |
UNCOVER-3 | A study in participants with moderate to severe psoriasis |
NF-kB | nuclear factor kappa light chain enhancer of activated B cells |
BSA | body surface area |
WHO | World Health Organisation |
References
- Parisi, R.; Symmons, D.; Griffiths, C.; Ashcroft, D.M. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. J. Investig. Dermatol. 2013, 133, 377–385. [Google Scholar] [CrossRef]
- Raychaudhuri, S.K.; Maverakis, E.; Raychaudhuri, S.P. Diagnosis and classification of psoriasis. Autoimmun. Rev. 2014, 13, 490–495. [Google Scholar] [CrossRef]
- Alinaghi, F.; Calov, M.; Kristensen, L.E.; Gladman, D.D.; Coates, L.C.; Jullien, D.; Gottlieb, A.B.; Gisondi, P.; Wu, J.J.; Thyssen, J.P.; et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J. Am. Acad. Dermatol. 2019, 80, 251–265.e19. [Google Scholar] [CrossRef]
- McCormick, T.; Ayala-Fontanez, N.; Soler, D. Current knowledge on psoriasis and autoimmune diseases. Psoriasis Targets Ther. 2016, 6, 7–32. [Google Scholar] [CrossRef]
- Toussirot, Ã.; Aubin, F.; Dumoulin, G.; Toussirot, É.; Aubin, F. Relationships between Adipose Tissue and Psoriasis, with or without Arthritis. Front. Immunol. 2014, 5. [Google Scholar] [CrossRef]
- Mehta, N.N.; Yu, Y.; Pinnelas, R.; Krishnamoorthy, P.; Shin, D.B.; Troxel, A.; Gelfand, J.M. Attributable Risk Estimate of Severe Psoriasis on Major Cardiovascular Events. Am. J. Med. 2011, 124, 775.e1–775.e6. [Google Scholar] [CrossRef]
- Armstrong, A.W.; Harskamp, C.T.; Armstrong, E.J. Psoriasis and metabolic syndrome: A systematic review and meta-analysis of observational studies. J. Am. Acad. Dermatol. 2013, 68, 654–662. [Google Scholar] [CrossRef]
- Ferdinando, L.B.; Fukumoto, P.K.; Sanches, S.; Fabricio, L.H.Z.; Skare, T.L. Metabolic syndrome and psoriasis: A study in 97 patients. Revista Associação Médica Brasileira 2018, 64, 368–373. [Google Scholar] [CrossRef] [PubMed]
- Kyle, U.G.; Bosaeus, I.; De Lorenzo, A.D.; Deurenberg, P.; Elia, M.; Gómez, J.M. Bioelectrical impedance analysis--part I: Review of principles and methods. Clin Nutr. 2004, 23, 1226–1243. [Google Scholar] [CrossRef] [PubMed]
- Kumar, S.; Dutt, A.; Hemraj, S.; Bhat, S.; Manipadybhima, B. Phase Angle Measurement in Healthy Human Subjects through Bio-Impedance Analysis. Iran J. Basic Med. Sci. 2012, 15, 1180–1184. [Google Scholar]
- Buch, E.; Bradfield, J.; Larson, T.; Horwich, T. Effect of Bioimpedance Body Composition Analysis on Function of Implanted Cardiac Devices. Pacing Clin. Electrophysiol. 2012, 35, 681–684. [Google Scholar] [CrossRef]
- Llamas-Velasco, M.; de la Cueva, P.; Notario, J.; Martínez-Pilar, L.; Martorell, A.; Moreno-Ramírez, D. Moderate Psoriasis: A Pro-posed Definition. Actas Dermosifiliogr. 2017, 108, 911–917. [Google Scholar] [CrossRef]
- Jin, Y.; Zhang, F.; Yang, S.; Kong, Y.; Xiao, F.; Hou, Y.; Fan, X.; Zhang, X. Combined effects of HLA-Cw6, body mass index and waist–hip ratio on psoriasis vulgaris in Chinese Han population. J. Dermatol. Sci. 2008, 52, 123–129. [Google Scholar] [CrossRef] [PubMed]
- Tupikowska-Marzec, M.; Kolačkov, K.; Zdrojowy-Wełna, A.; Słoka, N.K.; Szepietowski, J.C.; Maj, J. The Influence of FTO Polymorphism rs9939609 on Obesity, Some Clinical Features, and Disturbance of Carbohydrate Metabolism in Patients with Psoriasis. BioMed. Res. Int. 2019, 2019, 1–5. [Google Scholar] [CrossRef]
- von Stebut, E.; Boehncke, W.H.; Ghoreschi, K.; Gori, T.; Kaya, Z.; Thaci, D. IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications. Front. Immunol. 2019, 10, 3096. [Google Scholar] [CrossRef]
- Tang, Y.; Bian, Z.; Zhao, L.; Liu, Y.; Liang, S.; Wang, Q.; Han, X.; Peng, Y.; Chen, X.; Shen, L.; et al. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin. Exp. Immunol. 2011, 166, 281–290. [Google Scholar] [CrossRef]
- Chehimi, M.; Vidal, H.; Eljaafari, A. Pathogenic Role of IL-17-Producing Immune Cells in Obesity, and Related Inflammatory Diseases. J. Clin. Med. 2017, 6, 68. [Google Scholar] [CrossRef] [PubMed]
- Gisondi, P.; Targher, G.; Zoppini, G.; Girolomoni, G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J. Hepatol. 2009, 51, 758–764. [Google Scholar] [CrossRef]
- Shinjo, T.; Iwashita, M.; Yamashita, A.; Sano, T.; Tsuruta, M.; Matsunaga, H.; Sanui, T.; Asano, T.; Nishimura, F. IL-17A synergistically enhances TNFα-induced IL-6 and CCL20 production in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 2016, 477, 241–246. [Google Scholar] [CrossRef] [PubMed]
- Shin, J.H.; Shin, D.W.; Noh, M. Interleukin-17A inhibits adipocyte differentiation in human mesenchymal stem cells and regulates pro-inflammatory responses in adipocytes. Biochem. Pharmacol. 2009, 77, 1835–1844. [Google Scholar] [CrossRef] [PubMed]
- Gerdes, S.; Pinter, A.; Biermann, M.; Papavassilis, C.; Reinhardt, M. Adiponectin levels in a large pooled plaque psoriasis study population. J. Dermatol. Treat. 2019, 31, 531–534. [Google Scholar] [CrossRef]
- Baran, A.; Flisiak, I.; Jaroszewicz, J.; Świderska, M. Effect of psoriasis activity on serum adiponectin and leptin levels. Adv. Dermatol. Allergol. 2015, 2, 101–106. [Google Scholar] [CrossRef] [PubMed]
- Paiva-Lopes, M.J.; Batuca, J.; Gouveia, S.; Alves, M.; Papoila, A.L.; Alves, J.D. Antibodies towards high-density lipoprotein components in patients with psoriasis. Arch. Dermatol. Res. 2019, 312, 93–102. [Google Scholar] [CrossRef]
- Tan, E.; Baker, C.; Foley, P. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis. Australas. J. Dermatol. 2013, 54, 259–263. [Google Scholar] [CrossRef]
- Saraceno, R.; Schipani, C.; Mazzotta, A.; Esposito, M.; DiRenzo, L.; DeLorenzo, A.; Chimenti, S. Effect of anti-tumor necrosis factor-α therapies on body mass index in patients with psoriasis. Pharmacol. Res. 2008, 57, 290–295. [Google Scholar] [CrossRef]
- Montaudié, H.; Sbidian, E.; Paul, C.; Maza, A.; Gallini, A.; Aractingi, S.; Aubin, F.; Bachelez, H.; Cribier, B.; Joly, P.; et al. Methotrexate in psoriasis: A systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J. Eur. Acad. Dermatol. Venereol. 2011, 25, 12–18. [Google Scholar] [CrossRef] [PubMed]
- Gisondi, P.; Del Giglio, M.; Girolomoni, G. Considerations for Systemic Treatment of Psoriasis in Obese Patients. Am. J. Clin. Dermatol. 2016, 17, 609–615. [Google Scholar] [CrossRef] [PubMed]
- Gisondi, P.; Conti, A.; Galdo, G.; Piaserico, S.; de Simone, C.; Girolomoni, G. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: A prospective cohort study. Br. J. Dermatol. 2013, 168, 1124–1127. [Google Scholar] [CrossRef] [PubMed]
- Gordon, K.; Blauvelt, A.; Foley, P.; Song, M.; Wasfi, Y.; Randazzo, B.; Shen, Y.; You, Y.; Griffiths, C. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: A pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br. J. Dermatol. 2017, 178, 132–139. [Google Scholar] [CrossRef]
- Strober, B.; Menter, A.; Leonardi, C.; Gordon, K.; Lambert, J.; Puig, L.; Photowala, H.; Longcore, M.; Zhan, T.; Foley, P. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: An integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. J. Eur. Acad. Dermatol. Venereol. 2020, 34, 2830–2838. [Google Scholar] [CrossRef]
- Gerdes, S.; Pinter, A.; Papavassilis, C.; Reinhardt, M. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. J. Eur. Acad. Dermatol. Venereol. 2019, 34, 533–541. [Google Scholar] [CrossRef]
- Gisondi, P.; Bellinato, F.; Bruni, M.; De Angelis, G.; Girolomoni, G. Methotrexate vs secukinumab safety in psoriasis patients with metabolic syndrome. Dermatol. Ther. 2020, 33. [Google Scholar] [CrossRef] [PubMed]
- Wang, H.N.; Huang, Y.H. Changes in metabolic parameters in psoriatic patients treated with secukinumab. Ther. Adv. Chronic Dis. 2020, 11. [Google Scholar] [CrossRef] [PubMed]
- Egeberg, A.; Wu, J.J.; Korman, N.; Solomon, J.A.; Goldblum, O.; Zhao, F.; Mallbris, L. Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3. J. Am. Acad. Dermatol. 2018, 79, 104–109. [Google Scholar] [CrossRef] [PubMed]
- Huang, L.-H.; Zinselmeyer, B.H.; Chang, C.-H.; Saunders, B.T.; Elvington, A.; Baba, O.; Broekelmann, T.J.; Qi, L.; Rueve, J.S.; Swartz, M.A.; et al. Interleukin-17 Drives Interstitial Entrapment of Tissue Lipoproteins in Experimental Psoriasis. Cell Metab. 2019, 29, 475–487. [Google Scholar] [CrossRef] [PubMed]
- Al-Harbi, N.O.; Nadeem, A.; Al-Harbi, M.M.; Zoheir, K.M.; Ansari, M.A.; El-Sherbeeny, A.M.; Alanazi, K.M.; Alotaibi, M.R.; Ahmad, S.F. Psoriatic inflammation causes hepatic inflammation with concomitant dysregulation in hepatic metabolism via IL-17A/IL-17 receptor signaling in a murine model. Immunobiology. 2017, 222, 128–136. [Google Scholar] [CrossRef]
- Langan, S.M.; Seminara, N.M.; Shin, D.B.; Troxel, A.; Kimmel, S.E.; Mehta, N.N.; Margolis, D.J.; Gelfand, J.M. Prevalence of Metabolic Syndrome in Patients with Psoriasis: A Population-Based Study in the United Kingdom. J. Investig. Dermatol. 2012, 132, 556–562. [Google Scholar] [CrossRef] [PubMed]
- Choi, D.; Choi, S.; Son, J.S.; Oh, S.W.; Park, S.M. Impact of Discrepancies in General and Abdominal Obesity on Major Adverse Cardiac Events. J. Am. Hear. Assoc. 2019, 8, e013471. [Google Scholar] [CrossRef] [PubMed]
- Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech. Rep. Ser. 1995, 854, 1–452. [Google Scholar]
Patients’ Comorbidities | N (%) or Median (IQR) |
---|---|
Total sample | 35 (100) |
Sex | |
Women | 14 (40) |
Men | 21 (60) |
Age (years) | 49 (37–62) |
Disease duration (years) | 22 (13–27) |
BMI (kg/m2) | 32.8 (27.14–37.97) |
Psoriatic arthritis | 18 (51.42) |
Treatments | |
Bio-naive | 6 (17.14) |
Secukinumab | 22 (62.86) |
Ixekizumab | 13 (37.14) |
Characteristics | Baseline, Median (IQR) | 6-Month Follow-Up, Median (IQR) | p-Value (Wilcoxon Signed-Rank Test) |
---|---|---|---|
Clinical Characteristics | |||
PASI (0–72) | 18.00 (14–30) | 0.0 (0–4) | <0.001 |
DLQI (0–30) | 17.00 (10–27) | 0.0 (0–1) | <0.001 |
Laboratory Characteristics | |||
CRP (mg/L) | 6.60 (3.20–15.00) | 4.00 (2.10–5.60) | <0.001 |
ESR (mm/h) | 17.00 (5–37) | 7.00 (4–22) | 0.004 |
HDL-cholesterol (mmol/L) | 1.31 (1.16–1.53) | 1.40 (1.25–1.60) | 0.022 |
LDL-cholesterol (mmol/L) | 3.69 (2.75–4.24) | 3.19 (2.27–3.83) | 0.004 |
Total cholesterol (mmol/L) | 5.40 (4.40–6.50) | 5.26 (4.30–6.20) | 0.161 |
Triglyceride (mmol/L) | 1.52 (1.11–2.00) | 1.50 (1.10–2.38) | 0.116 |
Fasting glucose (mmol/L) | 5.60 (4.80–6.30) | 5.22 (4.70–6.40) | 0.640 |
AST (U/L) | 24.00 (19–35) | 24.00 (18–28) | 0.207 |
ALT (U/L) | 24.00 (18–43) | 24.00 (17–34) | 0.011 |
GGT (U/L) | 31.00 (21–65) | 28.00 (20–60) | 0.120 |
Characteristics | Baseline Median (IQR) | 6-Month Follow-Up Median (IQR) | p-Value (Wilcoxon Signed-Rank Test) |
---|---|---|---|
Body weight (kg) | 97.00 (75.70–111.00) | 96.70 (77.40–112.20) | 0.269 |
BMI (kg/m2) | 32.80 (27.14–37.97) | 32.80 (27.21–38.18) | 0.439 |
Fat-free mass (kg) | 55.20 (49.60–69.70) | 54.60 (48.6–70.60) | 0.895 |
FFMI (kg/m2) | 20.17 (18.76–21.88) | 20.00 (18.32–22.46) | 0.631 |
TBW (L) | 40.60 (36.40–51.10) | 40.60 (36.20–51.80) | 1.000 |
Protein (kg) | 10.80 (9.70–13.70) | 10.70 (9.40–14.00) | 0.741 |
Minerals (kg) | 3.67 (3.09–4.71) | 3.61 (3.25–4.75) | 0.405 |
Body fat mass (kg) | 33.30 (23.10–47.20) | 33.30 (24.20–46.70) | 0.548 |
BFMI (kg/m2) | 10.99 (7.87–17.22) | 11.15 (8.08–17.86) | 0.605 |
Body fat percent (%) | 37.10 (28.90–47.60) | 36.90 (29.00–47.30) | 0.885 |
Skeletal muscle mass (kg) | 30.80 (27.30–39.10) | 30.40 (26.40–40.50) | 0.727 |
SMMI (kg/m2) | 11.21 (10.30–12.11) | 11.09 (10.15–12.61) | 0.556 |
ECW ratio | 0.38 (0.38–0.39) | 0.38 (0.38–0.39) | 0.984 |
Phase Angle (◦) | 5.60 (5.00–6.00) | 5.60 (5.30–6.10) | 0.214 |
Visceral fat area (cm2) | 165.50 (115.20–229.20) | 164.20 (110.70–220.80) | 0.524 |
Body cell mass (kg) | 36.0 (32.20–45.20) | 35.60 (31.20–46.60) | 0.741 |
Bone mineral content (kg) | 3.06 (2.48–3.86) | 2.95 (2.583.91) | 0.561 |
ECW (L) | 15.70 (13.90–19.80) | 15.70 (13.90–19.50) | 0.698 |
ICW (L) | 25.10 (22.50–31.50) | 24.90 (21.80–32.60) | 0.709 |
InBody Score | 65.0 (53.0–72.0) | 65.0 (54.0–73.0) | 0.777 |
PASI (0–72) Change (N = 35) | CRP (mg/L) Change (N = 35) | ESR (mm/h) Change (N = 35) | HDL-cholesterol (mmol/L) Change (N = 35) | LDL-cholesterol (mmol/L) Change (N = 33) | |
---|---|---|---|---|---|
PASI (0–72) Change (N = 35) | - | 0.133 | 0.006 | −0.031 | 0.046 |
CRP (mg/L) Change(N = 35) | - | - | 0.424 * | −0.210 | 0.054 |
ESR (mm/h) Change(N = 35) | - | - | - | −0.001 | −0.007 |
HDL-cholesterol (mmol/L) Change (N = 35) | - | - | - | - | −0.180 |
LDL-cholesterol (mmol/L) Change (N = 33) | - | - | - | - | - |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Piros, É.A.; Szabó, Á.; Rencz, F.; Brodszky, V.; Wikonkál, N.; Miheller, P.; Horváth, M.; Holló, P. Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters’ Levels, but Has No Effect on Body Composition Parameters. Life 2021, 11, 535. https://doi.org/10.3390/life11060535
Piros ÉA, Szabó Á, Rencz F, Brodszky V, Wikonkál N, Miheller P, Horváth M, Holló P. Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters’ Levels, but Has No Effect on Body Composition Parameters. Life. 2021; 11(6):535. https://doi.org/10.3390/life11060535
Chicago/Turabian StylePiros, Éva Anna, Ákos Szabó, Fanni Rencz, Valentin Brodszky, Norbert Wikonkál, Pál Miheller, Miklós Horváth, and Péter Holló. 2021. "Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters’ Levels, but Has No Effect on Body Composition Parameters" Life 11, no. 6: 535. https://doi.org/10.3390/life11060535
APA StylePiros, É. A., Szabó, Á., Rencz, F., Brodszky, V., Wikonkál, N., Miheller, P., Horváth, M., & Holló, P. (2021). Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters’ Levels, but Has No Effect on Body Composition Parameters. Life, 11(6), 535. https://doi.org/10.3390/life11060535